Track market-moving stories before they get noisy

SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Girard Sharp LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of former Liberty Broadband Corporation (“Liberty Broadband”) investors who received shares of Charter Communications, Inc. (“Charter” or the “Company”) in connection with Charter’s acquisition of Liberty Broadband on August 20, 2026 (“Merger”).

CHARTER’S STOCK DROPS AFTER AUGUST MERGER

Charter Communications is a Connecticut–based broadband connectivity and cable operator that provides internet, television, mobile, and voice services. It’s the largest cable operator in the United States and serves 37 million customers. The Company states, “In 45 states across the country, our broadband, mobile, video and voice products power seamless connectivity and entertainment for our customers.” Since the closing of the Merger, the Company’s stock price has severely declined in value.

If you are a former Liberty Broadband investor who received Charter stock in the August 2026 merger and suffered losses, please fill out this form, email [email protected], or call (866) 981-4800 for a free consultation. 

Why Girard Sharp? 

Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We recently obtained a $36.5 million securities settlement against Maxar Technologies, a space imagery company, after its share price collapsed following its acquisition of DigitalGlobe. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal. 

Contact 

Girard Sharp LLP 

(866) 981-4800  

[email protected] 

[email protected] 

www.girardsharp.com 

Currently, 13 stocks traded on U.S. exchanges have a market capitalization of at least $1 trillion. Of those companies, Wall Street is most bullish on these three:

Among 56 analysts, Micron Technology (MU +2.96%) has a median target price of $1,575 per share. That implies 70% upside from its current share price of $925.Among 53 analysts, Broadcom has a median target price of $525 per share. That implies 54% upside from its current share price of $329.Among 72 analysts, Nvidia has a median target price of $320 per share. That implies 45% upside from its current share price of $219.The figures above suggest that Wall Street analysts view Micron as the best trillion-dollar stock to buy now. Here's what investors should know about the semiconductor company.

Image source: Getty Images.

Micron's profits are soaring due to a memory chip supply shortageMicron is a semiconductor company that manufactures memory chips and data storage solutions built on NAND flash and DRAM technology, including high-bandwidth memory (HBM). Its products are used in data centers, mobile devices, personal computers, and automotive systems.

Memory chips are currently in short supply due to immense demand for artificial intelligence infrastructure. The immediate consequence of that supply shortage is that DRAM and NAND prices have more than doubled in the last two years, and Micron's financial results have been impeccable.

In the September quarter, Micron's revenue increased 379% to $54 billion, and non-GAAP earnings soared to $33.42 per diluted share, an 11-fold increase from $3.03 per diluted share last year. And investors have good reason to think the company will maintain similar momentum in the coming years, as the memory chip supply shortage is likely to persist through at least 2028.

"Industry demand has strengthened since our last earnings call, and we expect memory and storage supply-demand conditions to be much tighter in fiscal 2027 and 2028 than they were in 2026," CEO Sanjay Mehrotra told analysts last month.

New memory chip production capacity could lead to oversupply by 2029The major memory chip suppliers are working to address supply constraints by adding production capacity. Micron earlier this year broke ground in New York on a new facility that will include up to four fabrication plants, making it the largest semiconductor manufacturing site in the U.S. The company is also constructing other wafer fabrication plants domestically and abroad.

Micron is not alone. Samsung is building DRAM facilities. SK Hynix is constructing DRAM, HBM, and NAND flash facilities, and it’s building an advanced packaging site. Meanwhile, Sandisk and Kioxia earlier this year opened a NAND flash facility, and Kioxia plans to build another NAND facility.

Memory chips from those new manufacturing sites will hit the market at various points over the next three years, potentially leading to oversupply by 2029. Historically, memory chip prices have fallen sharply during periods where supply outpaced demand, leading to large decreases in suppliers' earnings.

The last major downturn in the memory chip industry occurred during the aftermath of the pandemic. DRAM and NAND prices peaked in early 2021, then declined approximately 70% by late 2023. Against that backdrop, Micron stock declined 50% from its high at one point in 2022.

MU Micron Technology$904.90+$26.06 (+2.96%)

NASDAQ · As of 4:00 PM ET 10/19/26

Some investors think the current memory cycle will break the boom-and-bust moldIn the past, the memory chip industry has been highly cyclical, following a boom-and-bust pattern driven by fluctuations in supply and demand. Periods of strong demand would push prices higher, boosting suppliers' profits and incentivizing them to produce more chips. But they would invariably oversupply the market, causing prices and profits to fall.

Many investors see that pattern as a reason to be cautious in the current environment. But others think the AI revolution has changed the industry, potentially overcoming the traditional cycles by creating a powerful and durable source of demand. Indeed, Micron and other memory chip companies have signed longer contracts during the current cycle than in previous ones.

Also, conventional DRAM is a commodity because chips from different suppliers are largely interchangeable, meaning sellers compete heavily on price. However, HBM chips are more differentiated, so manufacturers compete on performance and power efficiency. As the AI boom unfolds and HBM becomes more important, memory chip suppliers could gain greater pricing power, potentially making the industry less susceptible to boom-and-bust cycles.

That puts investors in a difficult place. Micron stock looks quite cheap at 12 times earnings, especially because Wall Street estimates earnings will increase at 72% annually during the next three years. Then again, Micron traded at 6 times earnings at the low point of the last memory chip cycle. The stock would need to lose 50% of its value to reach that level today.
Personally, I think Micron is worth buying, but I would keep my position sizing  small because a steep decline in the future is certainly plausible. It’s dangerous to assume the current memory chip cycle will play out any differently than the last one.

Company Announces Quarterly Common Stock Dividend of $0.34 Per Share 

, /PRNewswire/ -- Synchrony Financial (NYSE: SYF) today announced its third quarter 2026 results for the period ending September 30, 2026. The earnings news release and presentation can be found on the company's Investor Relations website at https://investors.synchrony.com/financial-information/financial-results. 

Today at 8:00 a.m. Eastern Time, Brian Doubles, President and Chief Executive Officer, and Brian Wenzel Sr., Executive Vice President and Chief Financial Officer, will host a conference call to review the financial results and outlook for certain business drivers. The conference call can be accessed via an audio webcast through the investor relations website at www.investors.synchrony.com, under Events and Presentations. A replay will also be available on the website. 

The Company also announced that its Board of Directors (the "Board") declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on November 16, 2026 to holders of record at the close of business on November 5, 2026. The Board also declared a quarterly cash dividend on the outstanding shares of its 5.625% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A (the "Series A Preferred Stock"), 8.250% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the "Series B Preferred Stock") and 7.250% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C (the "Series C Preferred Stock"). Each outstanding share of Series A Preferred Stock and Series B Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share. Each outstanding share of Series C Preferred Stock is represented by depositary shares, each representing a 1/100th interest in a share. The dividends of approximately $14.06 per share on the Series A Preferred Stock (equivalent to $0.351563 per outstanding depositary share), approximately $20.63 per share on the Series B Preferred Stock (equivalent to $0.515625 per outstanding depositary share) and approximately $1,812.50 per share on the Series C Preferred Stock (equivalent to $18.125 per outstanding depositary share) are payable on November 16, 2026 to holders of record at the close of business on November 5, 2026.

About Synchrony 
Synchrony (NYSE: SYF) is a leading consumer financing company that has been at the heart of American commerce and opportunity for nearly a century. Synchrony delivers credit and banking products that empower tens of millions of consumers to improve their financial lives and access what matters most. Leveraging innovative solutions that are shaping the future of retail commerce, Synchrony supports the growth and success of some of the nation's most respected brands, alongside hundreds of thousands of small and midsize businesses, including health and wellness providers. Committed to excellence in service and culture, Synchrony is honored to be ranked the #1 Best Company to Work For® in the U.S. by Fortune magazine and Great Place to Work®. For more information, visit www.synchrony.com. 

Contacts 
Investor Relations: 
Kathryn Miller 
(203) 585-6291 
[email protected] 

Media Relations: 
Ashley Tufts
(203) 212-6277
[email protected]

SOURCE Synchrony

State of Alaska Department of Revenue increased its stake in Avient Corporation (NYSE:AVNT – Free Report) by 214.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,198 shares of the company’s stock after purchasing an additional 28,792 shares during the quarter. State of Alaska Department of Revenue’s holdings in Avient were worth $1,697,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Avient during the 2nd quarter valued at about $437,002,000. Dimensional Fund Advisors LP raised its position in shares of Avient by 4.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,973,887 shares of the company’s stock worth $180,546,000 after buying an additional 192,788 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Avient by 2.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,012,847 shares of the company’s stock worth $111,355,000 after acquiring an additional 78,938 shares during the period. Jennison Associates LLC lifted its stake in shares of Avient by 96.0% in the 1st quarter. Jennison Associates LLC now owns 1,411,254 shares of the company’s stock worth $51,229,000 after acquiring an additional 691,316 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Avient in the 2nd quarter worth approximately $45,933,000. Institutional investors own 95.48% of the company’s stock.

Avient Price Performance Shares of Avient stock opened at $39.52 on Tuesday. The company has a current ratio of 1.90, a quick ratio of 1.35 and a debt-to-equity ratio of 0.77. The company’s 50-day moving average price is $42.12 and its two-hundred day moving average price is $38.58. Avient Corporation has a 52 week low of $27.48 and a 52 week high of $46.64. The stock has a market cap of $3.62 billion, a PE ratio of 21.36, a price-to-earnings-growth ratio of 1.13 and a beta of 1.28.

Avient (NYSE:AVNT – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.07. Avient had a net margin of 5.10% and a return on equity of 11.64%. The company had revenue of $917.00 million during the quarter, compared to the consensus estimate of $898.53 million. During the same period in the prior year, the company earned $0.80 EPS. Avient’s revenue was up 5.8% on a year-over-year basis. Avient has set its FY 2026 guidance at 3.100-3.250 EPS and its Q3 2026 guidance at 0.800-0.800 EPS. As a group, sell-side analysts anticipate that Avient Corporation will post 3.20 EPS for the current fiscal year. Avient Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, December 11th will be paid a dividend of $0.2825 per share. This is a boost from Avient’s previous quarterly dividend of $0.2750. This represents a $1.13 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 11th. Avient’s dividend payout ratio (DPR) is currently 59.46%.

Analyst Upgrades and Downgrades AVNT has been the topic of a number of research analyst reports. Barclays initiated coverage on shares of Avient in a research note on Monday, October 12th. They set an “equal weight” rating and a $44.00 price objective on the stock. Wall Street Zen cut Avient from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research upgraded Avient from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 29th. Seaport Research Partners reaffirmed a “buy” rating and set a $54.00 price target on shares of Avient in a research note on Friday, August 7th. Finally, Truist Financial increased their price target on Avient from $44.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.38.

View Our Latest Research Report on Avient

Avient Profile (Free Report)

Avient Corporation (NYSE: AVNT) is a global provider of specialized and sustainable polymer materials. The company develops, formulates and manufactures engineered materials, colorants, additives and performance-enhancing solutions used to improve the appearance, durability, processing and functionality of plastic products.

Its offerings include specialty polymer formulations, thermoplastic compounds, color and additive concentrates, advanced composites, barrier technologies and recycled or bio-based material solutions.

Further Reading Five stocks we like better than Avient Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears? Want to see what other hedge funds are holding AVNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avient Corporation (NYSE:AVNT – Free Report).

Receive News & Ratings for Avient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avient and related companies with MarketBeat.com's FREE daily email newsletter.

Crane (NYSE:CR – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Crane to announce earnings of $1.82 per share and revenue of $737.04 million for the quarter. Crane has set its FY 2026 guidance at 6.850-7.050 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 10:00 AM ET.

Crane (NYSE:CR – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The conglomerate reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.11. The business had revenue of $724.70 million for the quarter, compared to analyst estimates of $708.46 million. Crane had a net margin of 12.97% and a return on equity of 18.67%. The business’s revenue for the quarter was up 25.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.49 earnings per share. On average, analysts expect Crane to post $6.99 EPS for the current fiscal year and $7.76 EPS for the next fiscal year.

Crane Stock Performance Shares of CR stock opened at $206.03 on Tuesday. The business’s fifty day simple moving average is $205.92 and its 200-day simple moving average is $201.08. The company has a market cap of $11.91 billion, a PE ratio of 36.02, a PEG ratio of 2.45 and a beta of 1.02. The company has a current ratio of 2.80, a quick ratio of 1.84 and a debt-to-equity ratio of 0.50. Crane has a 12-month low of $159.58 and a 12-month high of $230.50.

Crane Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 9th. Stockholders of record on Monday, August 31st were given a $0.2550 dividend. The ex-dividend date of this dividend was Monday, August 31st. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.5%. Crane’s dividend payout ratio (DPR) is presently 17.83%. Insider Transactions at Crane In other Crane news, Director James Tullis sold 614 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $225.00, for a total transaction of $138,150.00. Following the transaction, the director owned 5,421 shares in the company, valued at approximately $1,219,725. This represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.12% of the company’s stock.

Wall Street Analysts Forecast Growth Several brokerages recently weighed in on CR. Stifel Nicolaus boosted their target price on Crane from $215.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Weiss Ratings raised Crane from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. BMO Capital Markets initiated coverage on Crane in a research note on Monday, July 20th. They issued an “outperform” rating and a $253.00 price target for the company. Deutsche Bank Aktiengesellschaft set a $240.00 price target on Crane in a research note on Tuesday, September 1st. Finally, DA Davidson reissued a “buy” rating and issued a $245.00 price target on shares of Crane in a report on Tuesday, September 15th. Three equities research analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $239.00.

Read Our Latest Analysis on Crane

About Crane (Get Free Report)

Crane Company (NYSE: CR) is a diversified industrial technology company that develops and manufactures highly engineered products for aerospace, industrial, commercial and other specialized markets. The company serves customers worldwide through businesses focused on mission-critical components, systems and services.

Its Aerospace & Electronics segment supplies products such as sensing and control systems, aircraft components, power-management equipment and other electronic solutions for commercial and military aerospace applications.

Read More Five stocks we like better than Crane Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Receive News & Ratings for Crane Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crane and related companies with MarketBeat.com's FREE daily email newsletter.

State of Alaska Department of Revenue lowered its holdings in Archrock, Inc. (NYSE:AROC – Free Report) by 32.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 57,559 shares of the energy company’s stock after selling 27,893 shares during the quarter. State of Alaska Department of Revenue’s holdings in Archrock were worth $1,742,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Archrock in the second quarter valued at $1,217,511,000. Bank of America Corp DE bought a new position in shares of Archrock in the second quarter valued at about $262,070,000. Bank of New York Mellon Corp bought a new position in shares of Archrock in the second quarter valued at about $84,463,000. Energy Income Partners LLC acquired a new position in Archrock during the 2nd quarter worth about $58,510,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Archrock during the 2nd quarter worth about $51,617,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analyst Ratings Changes AROC has been the topic of a number of research analyst reports. Wells Fargo & Company decreased their price objective on shares of Archrock from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. Royal Bank Of Canada boosted their target price on shares of Archrock from $44.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 17th. Zacks Research downgraded shares of Archrock from a “hold” rating to a “strong sell” rating in a research note on Monday, August 31st. Weiss Ratings lowered shares of Archrock from a “buy (a-)” rating to a “buy (b)” rating in a research report on Tuesday, August 11th. Finally, Evercore set a $40.00 target price on shares of Archrock in a research report on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Archrock presently has a consensus rating of “Moderate Buy” and an average target price of $42.12.

View Our Latest Stock Report on AROC Archrock Stock Down 0.7% Shares of NYSE:AROC opened at $29.36 on Tuesday. Archrock, Inc. has a one year low of $22.88 and a one year high of $42.23. The company has a 50 day moving average of $31.41 and a 200-day moving average of $34.81. The company has a debt-to-equity ratio of 1.51, a current ratio of 1.39 and a quick ratio of 0.94. The stock has a market cap of $5.15 billion, a price-to-earnings ratio of 15.48, a P/E/G ratio of 1.43 and a beta of 0.92.

Archrock (NYSE:AROC – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The energy company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.07). Archrock had a return on equity of 22.22% and a net margin of 21.84%. The business had revenue of $371.24 million for the quarter, compared to the consensus estimate of $393.19 million. During the same period last year, the firm earned $0.39 earnings per share. The company’s quarterly revenue was down 3.1% on a year-over-year basis. On average, sell-side analysts forecast that Archrock, Inc. will post 1.72 earnings per share for the current year.

Archrock Increases Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 11th. Shareholders of record on Tuesday, August 4th were given a dividend of $0.23 per share. This represents a $0.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date was Tuesday, August 4th. This is a positive change from Archrock’s previous quarterly dividend of $0.22. Archrock’s dividend payout ratio is presently 49.46%.

Archrock Company Profile (Free Report)

Archrock, Inc (NYSE: AROC) is a Houston-based energy infrastructure company that provides natural gas compression services in the United States. Compression is used to increase the pressure of natural gas so it can move efficiently through gathering systems, processing facilities, transmission pipelines and other midstream infrastructure.

The company operates a fleet of natural gas compressors and primarily serves customers through contract compression arrangements. Its services support a range of applications, including natural gas gathering, processing, transmission, storage and production.

Recommended Stories Five stocks we like better than Archrock Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears? Want to see what other hedge funds are holding AROC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Archrock, Inc. (NYSE:AROC – Free Report).

Receive News & Ratings for Archrock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Archrock and related companies with MarketBeat.com's FREE daily email newsletter.

Universal Health Services (NYSE:UHS – Get Free Report) is expected to announce its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Universal Health Services to post earnings of $5.20 per share and revenue of $4.71 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Universal Health Services (NYSE:UHS – Get Free Report) last posted its earnings results on Tuesday, July 28th. The health services provider reported $5.98 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.04. The firm had revenue of $4.64 billion during the quarter, compared to the consensus estimate of $4.58 billion. Universal Health Services had a net margin of 8.42% and a return on equity of 19.39%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $5.35 earnings per share. On average, analysts expect Universal Health Services to post $22.86 EPS for the current fiscal year and $24.07 EPS for the next fiscal year.

Universal Health Services Price Performance UHS opened at $182.61 on Tuesday. The firm has a 50-day moving average price of $175.54 and a 200-day moving average price of $166.24. Universal Health Services has a twelve month low of $140.08 and a twelve month high of $246.32. The company has a quick ratio of 1.04, a current ratio of 1.12 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $10.76 billion, a price-to-earnings ratio of 7.44, a PEG ratio of 1.14 and a beta of 1.03.

Analysts Set New Price Targets Several research firms recently commented on UHS. The Goldman Sachs Group cut their price objective on shares of Universal Health Services from $242.00 to $190.00 and set a “neutral” rating for the company in a report on Thursday, July 30th. Wells Fargo & Company lifted their price objective on shares of Universal Health Services from $165.00 to $166.00 and gave the company an “equal weight” rating in a research note on Monday, July 13th. Morgan Stanley lowered their target price on shares of Universal Health Services from $212.00 to $191.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Weiss Ratings upgraded Universal Health Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, October 14th. Finally, UBS Group restated a “buy” rating on shares of Universal Health Services in a research report on Monday, August 31st. Six equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $204.94. Get Our Latest Stock Analysis on Universal Health Services

Universal Health Services Company Profile (Get Free Report)

Universal Health Services, Inc (NYSE: UHS) is a healthcare services company that owns and operates hospitals, outpatient facilities and other healthcare providers. Its operations are focused primarily on acute care and behavioral health services.

The company’s acute care operations include general and specialty hospitals, ambulatory surgery centers, emergency departments, physician practices and other outpatient services. Its behavioral health business provides inpatient and outpatient treatment for mental health conditions, substance-use disorders and related needs.

Universal Health Services serves patients across the United States and Puerto Rico, with additional behavioral health operations in the United Kingdom.

Read More Five stocks we like better than Universal Health Services Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Receive News & Ratings for Universal Health Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universal Health Services and related companies with MarketBeat.com's FREE daily email newsletter.

Chemed (NYSE:CHE – Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of $6.39 per share and revenue of $685.04 million for the quarter. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 10:00 AM ET.

Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. During the same period in the previous year, the business posted $4.27 earnings per share. Chemed’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts expect Chemed to post $23.55 EPS for the current fiscal year and $25.17 EPS for the next fiscal year.

Chemed Price Performance Shares of NYSE:CHE opened at $508.20 on Tuesday. The company has a 50-day simple moving average of $516.74 and a 200-day simple moving average of $472.72. Chemed has a one year low of $365.20 and a one year high of $557.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 2.06 and a beta of 0.51.

Chemed Increases Dividend The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were issued a dividend of $0.70 per share. This is an increase from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 17th. Chemed’s dividend payout ratio is 14.06%. Insiders Place Their Bets In other Chemed news, EVP Spencer Lee sold 1,000 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the transaction, the executive vice president owned 13,912 shares in the company, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin McNamara sold 2,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the sale, the chief executive officer owned 70,418 shares of the company’s stock, valued at $37,991,215.18. This trade represents a 2.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 9,190 shares of company stock worth $4,833,160. 3.33% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth CHE has been the topic of several recent research reports. Wall Street Zen upgraded Chemed from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 10th. UBS Group started coverage on Chemed in a research note on Friday, September 25th. They set a “buy” rating and a $650.00 price objective for the company. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. Weiss Ratings upgraded Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Oppenheimer upped their price target on Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $554.60.

Check Out Our Latest Analysis on Chemed

Chemed Company Profile (Get Free Report)

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.

Featured Stories Five stocks we like better than Chemed Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Marvell Technology (MRVL +4.06%) is deeply involved in artificial intelligence infrastructure, with its optical chips, application-specific integrated circuits (ASICs), data storage controllers, and CXL memory products. This broad portfolio of products explains why Nvidia CEO Jensen Huang said back in June that he expects Marvell Technology to be the next $1 trillion company.

Given its current market cap of around $215 million, that prediction implies a nearly 5x return from current levels, a gain that could help mint many new millionaires, and the fundamentals certainly look promising. Here's what investors should know.

Image source: Getty Images.

Marvell's long-term deal with Alphabet gives it a massive backlog
Marvell Technology is already doing well. In its fiscal 2027 second quarter, which ended Aug. 1, the company delivered 37% year-over-year revenue growth, with "AI-related bookings remain[ing] exceptionally robust," according to Marvell Technology CEO Matt Murphy. He also expects AI revenue to accelerate further in fiscal 2027, prompting the company to raise its guidance for fiscal 2027 and 2028.

$237.09+$9.26 (+4.06%)

NASDAQ · As of 4:00 PM ET 10/19/26

Moreover, after that quarter ended (but before its report came out), the company announced a big expansion of its AI chip deal with Alphabet. It amounts to $120 billion over roughly six and a half years, and that business arrangement starts in Marvell's fiscal 2029.

Marvell Technology will continue to strengthen its market position in the meantime, and if it can land big deals like that with other tech giants, it could see an extended rally. Marvell Technology generated $2.74 billion in sales in its fiscal Q2 while boosting net profit margins, and its guidance for the upcoming quarter implies 15% sequential revenue growth at the midpoint.

A high valuation is the price of entry
Although Marvell Technology has several attractive catalysts ahead of it, the stock isn't cheap. It trades at a forward P/E ratio of 62. Other chipmakers such as Broadcom and Nvidia offer cheaper valuations and solid growth prospects. Furthermore, those two companies are exhibiting higher revenue growth rates than Marvell Technology.

While Nvidia and Broadcom look more attractive if you only consider next year, Marvell Technology may be the better choice when considered over a five-year time horizon. Its big deal with Alphabet will contribute roughly $5 billion per quarter in sales once it starts, and that's almost two times Marvell Technology's Q2 FY27 revenue.

Marvell Technology is still of a size where a single new contract of that magnitude can change the investment thesis in the stock overnight. Nvidia is on its way to more than $100 billion in quarterly revenue, so it would need multiple large contracts to sustain meaningful growth. Marvell Technology is well-positioned to gain market share as optical chips and ASICs gain traction. A few more major contracts could spark a rally that lifts its market cap closer to Jensen Huang's $1 trillion prediction.

Marc Guberti has positions in Broadcom. The Motley Fool has positions in and recommends Alphabet, Broadcom, Marvell Technology, and Nvidia. The Motley Fool has a disclosure policy.

Five-year agreement will help simplify and modernize Ingenico's global technology operations

, /PRNewswire/ -- Cognizant (Nasdaq: CTSH) today announced that it has been chosen by Ingenico, the smart technology powering in-person commerce, as its global strategic technology partner. Under the five-year agreement, Cognizant has been tasked with embedding AI across Ingenico's infrastructure and operations, security and data to support the modernization of Ingenico's technology operations, including infrastructure, security, business and corporate applications and data systems, while providing managed services across end-user services, service desk, application support and engineering.

Every day, Ingenico's smart technology powers millions of interactions worldwide, helping businesses deliver better customer experiences, build loyalty and drive growth. By combining seamless payment acceptance with powerful data and insights, Ingenico enables customers to reduce complexity and get more from every interaction, all backed by the security, reliability and trust the company is known for. To support its next phase of growth and innovation, Ingenico sought a strategic technology partner to simplify and modernize its technology operations and create a scalable foundation for future growth.

Cognizant will support the consolidation and modernization of Ingenico's IT environment, helping strengthen security, improve operational efficiency and increase agility across the business.

"The payments industry continues to evolve rapidly, with growing demands around security, resilience, operational efficiency and innovation," said Rohit Gupta, UK&I Managing Director at Cognizant. "We're proud to have been selected by Ingenico as a strategic partner. Together, we'll help modernize key operations, strengthen core technology foundations and support Ingenico's long-term growth ambitions."

"At Ingenico, we're constantly evolving our technology and capabilities to help our customers grow, simplify complexity and deliver superior customer experiences," commented Tim Fulton, CIO at Ingenico. "As we looked for a partner to support the next phase of that journey, Cognizant stood out through its industry expertise, global scale and understanding of our business. Together, we will modernize key IT operations, strengthen the foundations that underpin the trusted solutions our customers rely on, and increase agility across the business to support future growth and innovation."

About Cognizant
Cognizant (NASDAQ: CTSH) is an AI builder and technology services provider, building the bridge between AI investment and enterprise value by building full-stack AI solutions for our clients. Our deep industry, process and engineering expertise enables us to build an organization's unique context into technology systems that amplify human potential, realize tangible returns and keep global enterprises ahead in a fast-changing world. See how at www.cognizant.ai or @cognizant.

About Ingenico 
Ingenico is the smart technology powering in-person commerce. Every day, its intelligent solutions help businesses turn millions of payment interactions into opportunities to deliver superior customer experiences, build loyalty and increase revenue. 

With more than four decades of innovation and expertise, over 3,000 employees worldwide, and tens of millions of devices deployed across more than 120 countries, Ingenico combines seamless acceptance with powerful data and insights. Its intelligent solutions help businesses reduce complexity, grow faster and get more from every customer interaction, backed by the reliability, security and trust for which Ingenico is known. For more information, visit www.ingenico.com

Media contacts:

U.S.
Alex Dudley
[email protected] 

Europe / APAC
Sarah Douglas
[email protected] 

India
Vipin Nair
[email protected] 

SOURCE Cognizant Technology Solutions

State of Alaska Department of Revenue lowered its stake in Glaukos Corporation (NYSE:GKOS – Free Report) by 48.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,950 shares of the medical instruments supplier’s stock after selling 9,393 shares during the period. State of Alaska Department of Revenue’s holdings in Glaukos were worth $1,633,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of Glaukos during the 2nd quarter worth $28,000. CoreCap Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter worth $33,000. Fortitude Family Office LLC acquired a new stake in shares of Glaukos during the third quarter worth $36,000. Parallel Advisors LLC raised its position in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the period. Finally, IFP Advisors Inc raised its position in shares of Glaukos by 523.4% during the second quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 246 shares during the period. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance NYSE GKOS opened at $166.98 on Tuesday. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average price is $172.08 and its two-hundred day moving average price is $148.69.

Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company’s revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.24) EPS. As a group, sell-side analysts forecast that Glaukos Corporation will post -0.32 earnings per share for the current year. Insiders Place Their Bets In related news, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at approximately $7,908,787.78. This represents a 31.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph Gilliam sold 60,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 83,025 shares of company stock worth $14,950,006. 5.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes A number of equities analysts recently weighed in on the company. Stifel Nicolaus increased their price target on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Truist Financial lifted their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. UBS Group initiated coverage on Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price objective on the stock. Jefferies Financial Group boosted their price objective on Glaukos from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Finally, Needham & Company LLC upped their price objective on shares of Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.43.

Check Out Our Latest Report on Glaukos

Glaukos Profile (Free Report)

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.

Featured Stories Five stocks we like better than Glaukos Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears? Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Highwoods Properties (NYSE:HIW – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.2131 per share and revenue of $215.61 million for the quarter. Highwoods Properties has set its FY 2026 guidance at 3.460-3.700 EPS. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 11:00 AM ET.

Highwoods Properties (NYSE:HIW – Get Free Report) last issued its earnings results on Tuesday, July 28th. The real estate investment trust reported $0.85 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.01). The company had revenue of $216.38 million during the quarter, compared to the consensus estimate of $212.15 million. Highwoods Properties had a return on equity of 7.06% and a net margin of 20.74%. Highwoods Properties’s revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 earnings per share. On average, analysts expect Highwoods Properties to post $3.55 EPS for the current fiscal year and $3.66 EPS for the next fiscal year.

Highwoods Properties Stock Performance
Shares of NYSE:HIW opened at $28.50 on Tuesday. The firm has a market cap of $3.14 billion, a PE ratio of 18.75 and a beta of 1.06. The firm’s 50 day simple moving average is $30.38 and its 200-day simple moving average is $28.82. Highwoods Properties has a one year low of $20.45 and a one year high of $35.44. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.68 and a current ratio of 1.68.

Highwoods Properties Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Wednesday, September 9th. Investors of record on Monday, August 17th were issued a $0.50 dividend. The ex-dividend date was Monday, August 17th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 7.0%. Highwoods Properties’s payout ratio is presently 131.58%.
Analyst Upgrades and Downgrades
HIW has been the topic of several research analyst reports. Weiss Ratings raised Highwoods Properties from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft downgraded Highwoods Properties from a “buy” rating to a “hold” rating and set a $33.00 price objective on the stock. in a report on Wednesday, August 5th. Wells Fargo & Company lifted their target price on Highwoods Properties from $26.00 to $32.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 1st. Morgan Stanley lifted their target price on Highwoods Properties from $23.00 to $35.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. Finally, Citigroup upped their target price on Highwoods Properties from $24.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Highwoods Properties presently has an average rating of “Hold” and an average price target of $32.00.

Read Our Latest Stock Analysis on Highwoods Properties

(Get Free Report)

Highwoods Properties, Inc (NYSE: HIW) is a real estate investment trust that owns, develops, leases and manages primarily office properties. The company focuses on high-quality buildings in prominent business districts and serves corporate, professional-services and other commercial tenants.

Highwoods’ portfolio is concentrated in major Sun Belt and Southeast markets, including Atlanta, Charlotte, Orlando, Raleigh, Richmond, Nashville and Tampa. In addition to leasing office space, the company provides property management and related services and pursues select development and redevelopment opportunities to support its portfolio.

Founded in 1978, Highwoods Properties became a publicly traded company in 1994.

See Also

Five stocks we like better than Highwoods Properties
Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Receive News & Ratings for Highwoods Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Highwoods Properties and related companies with MarketBeat.com's FREE daily email newsletter.

New Teradata Factory and Teradata Sovereign Cloud on Google Distributed Cloud capabilities give enterprises greater control over where their most sensitive data and AI operate

, /PRNewswire/ -- Teradata (NYSE: TDC) today announced a portfolio of deployment and platform capabilities designed to give governments and enterprises greater control over the data, AI, and technology that power their most critical operations. This includes expanded capabilities for Teradata Factory with AI Studio and the availability of Teradata Sovereign Cloud on Google Distributed Cloud air-gapped environment.

What's New
Teradata's portfolio spans two complementary deployment models designed to address different sovereignty requirements.

The expanded capabilities for Teradata Factory with AI Studio bring a unified AI environment to operate on data, vectors, models, and agents directly into customer-controlled on-premises infrastructure. These capabilities include:

Tera, the agentic coworker for enterprise data work, including Tera Harness and Tera Context Engine
AgentStack, the complete AI agent development capabilities to build, manage, observe and operate agents through natural language, pro-code, low-code, and Model Context Protocol (MCP) interfaces
Model services, which provide machine learning operations and AI model management with pre-integrated model and bring-your-own-model support
Data pipelines for ingesting multimodal unstructured data, vector embeddings, vector storage and hybrid search for RAG
Analytics, native notebooks backed by in-database analytics and Teradata's Elastic Python Compute, built on Ray and Arrow, bring AI to where data lives

Teradata Sovereign Cloud on Google Distributed Cloud air-gapped brings Teradata's high-performance enterprise-scale analytics into fully isolated environments. Key benefits of running Teradata Sovereign Cloud on Google Distributed Cloud air-gapped include:

Full isolation: Deploy Teradata in an air-gapped environment with no external connectivity— keeping classified and regulated data fully contained
Security and compliance: Meet stringent regulatory requirements while maintaining complete audit trails and governance
High-performance analytics and AI at scale: Run complex queries across billions of rows and petabytes of data with predictable performance

Why it Matters
Research points to growing urgency. According to a 2026 BARC global study of 320 business and IT decision-makers, 62 percent of organizations cite data and AI in core business processes as a key driver of sovereignty requirements. A separate IBM study found that 91 percent of executives say they do not fully understand their organization's dependencies across AI vendors, models and infrastructure. And Gartner predicts that by 2030, more than 75 percent of enterprises outside the United States will have a digital sovereignty strategy, supported by a sovereign cloud strategy.

As AI moves into mission-critical operations, sovereignty is no longer only about where data resides. Organizations must also consider where AI runs, which models are used, how enterprise information is accessed, who operates the environment, and which external technologies their AI depends on.

This is particularly relevant for governments, defense organizations, regulated industries and critical infrastructure, where data residency, privacy, jurisdiction, operational continuity or national-security requirements can limit the use of traditional public-cloud AI services.

Teradata frames sovereignty across three dimensions: data sovereignty (where data lives and who can access it), operational sovereignty (who controls the environment and whether it can operate independently), and digital sovereignty (which technologies and AI models the organization depends on). An organization can satisfy data residency requirements and still lack full sovereignty if AI processing occurs externally, external administrators can access the environment, or operations stop when public connectivity is unavailable.

Teradata's sovereign portfolio is designed to address these requirements, bringing enterprise analytics and AI inside the boundaries that organizations control.

The Deployment Portfolio
Teradata Factory and Teradata Sovereign Cloud on Google Distributed Cloud air-gapped address different sovereignty requirements.

Teradata Factory is an integrated hardware and software rack that brings a private enterprise data and AI environment into customer-controlled on-premises infrastructure. It is designed for organizations that require direct physical control over their infrastructure and AI execution.

Teradata Sovereign Cloud on Google Distributed Cloud air-gapped provides a cloud operating model inside a sovereign boundary. The environment has no connection to the public internet and is operated by the customer. It is designed for organizations that need the operational model of cloud within a fully isolated, sovereign environment. Teradata provides the enterprise analytics layer within the air-gapped boundary, enabling organizations to support use cases such as operational reporting, mission analysis, intelligence fusion, training and simulation analytics, and defense logistics and sustainment inside the sovereign boundary.

Together, Teradata Factory and Teradata Sovereign Cloud on Google Distributed Cloud air-gapped support a hybrid approach to sovereign deployment, giving organizations the flexibility to run enterprise analytics and AI inside whichever boundary their requirements demand.

Executive Perspectives
"As AI becomes embedded in mission-critical decisions, organizations can no longer treat sovereignty as a data-location requirement. They need control over where AI runs, which models are used, who can operate the environment, and whether critical workloads can continue if external connectivity disappears. And increasingly, sovereignty is not a single location. It is an architecture that spans public cloud, sovereign cloud, and on-premises infrastructure. Teradata is uniquely built for that reality. We can run in all of those environments, connect them through Teradata Fabric without requiring data to move, and give organizations the freedom to choose the AI models and infrastructure that work for them."

— Sumeet Arora, Chief Product Officer, Teradata

"Google Distributed Cloud is purpose-built, air-gapped infrastructure that delivers complete technical, operational and software sovereignty. By combining Google Distributed Cloud's sovereign infrastructure with Teradata's AI and knowledge capabilities, we are giving enterprise customers in regulated industries the ability to innovate without sacrificing control over their data."

— Muninder Singh Sambi, VP of Product Management, Google Distributed Cloud

Availability
The expanded Teradata sovereign capabilities for Teradata Factory with AI Studio will be available in Q1 2027. Teradata Sovereign Cloud on Google Distributed Cloud air-gapped is available in Private Preview.

About Teradata
Teradata empowers enterprises to turn intelligence into autonomous action, grounding AI agents in deep business context and trusted data. As AI agents multiply, Teradata is the context foundation, governance layer, and performance backbone that companies need now. The Teradata Autonomous Knowledge Platform puts AI into production across cloud, on-premises, and hybrid environments.

Teradata Forward-Looking Statements
This press release contains "forward-looking statements" about the expectations, beliefs, plans, and intentions relating to Teradata's sovereign portfolio. Such statements include statements regarding future product availability, capabilities, and offerings, and expected benefits to Teradata customers. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, Teradata's results could differ materially from the results expressed or implied by the forward-looking statements made. Teradata undertakes no obligation, and does not intend to update the forward-looking statements. Factors that may cause actual results to differ materially from those in any forward-looking statements include: (i) delays and unexpected difficulties and expenses in executing the planned product capabilities and offerings, (ii) changes in the regulatory landscape related to AI and (iii) uncertainty as to whether customer adoption will justify the investments in the product capabilities and offerings. Further information on factors that could affect Teradata's financial and other results is included in the filings Teradata makes with the Securities and Exchange Commission from time to time.

The Teradata logo is a trademark, and Teradata is a registered trademark of Teradata Corporation and/or its affiliates in the U.S. and worldwide.

MEDIA CONTACT
January Machold
[email protected]

SOURCE Teradata Corporation

Artificial intelligence (AI) stocks have led this bull market over the past three years, pushing the S&P 500 to record highs. Investors were eager to get in on this promising technology early on, and in many cases, they've already greatly benefited. For example, chip designers such as Nvidia and Advanced Micro Devices, as well as cloud companies like Alphabet, have seen revenue and stock performance march higher.

In recent weeks, though, AI stocks have faced various headwinds, from general concerns about the economy to questions about AI spending. The spending issue has emerged as a key risk: If the revenue opportunity doesn't match these companies' spending levels, their earnings and stock performance could suffer.

Considering this, investors are seeking clues about the future AI opportunity. And they might gather some on Oct. 21, after the market closes. For this reason, my prediction is that this day and the one to follow might be huge for the stock market. Let's find out exactly what's on the agenda and zoom in on the details.

Image source: Getty Images.

Earnings season for tech giantsSo, what's happening on Oct. 21? The first of the "Magnificent Seven" companies involved in the AI race is set to report third-quarter earnings. These companies are Amazon, Alphabet, Apple, Meta Platforms (META -0.55%), Microsoft, Nvidia, and Tesla. Earnings season kicked off earlier this month, with reports from financial companies, and as of this week, the biggest tech companies will begin reporting.

And the company to kick things off is Meta. You might best associate this tech giant with social media, due to its ownership of Facebook, Messenger, Instagram, and WhatsApp. These are among the world's most popular social media apps, with 3.6 billion people using at least one every day. They also have been the major driver of revenue for Meta, with advertisers paying to access space across these apps.

META Meta Platforms$705.44-$3.89 (-0.55%)

NASDAQ · As of 4:00 PM ET 10/19/26

In the latest quarter, this generated a 28% gain in total revenue to $60 billion, with ad revenue making up $59 billion. And over time, this revenue stream has pushed earnings higher.

In recent years, though, Meta broadened its focus to include AI -- and it's betting heavily that this business will be a major part of its future earnings opportunity. Meta has spent billions of dollars on data center build-out, the development of its own large language models, and the hiring of a rock-solid team of AI experts to lead the way.

Investing in AI infrastructureAs this started to unfold, some investors worried about the levels of investment, and this weighed on Meta's stock performance during certain moments of the AI story. Meta's capital spending-to-revenue ratio, a metric measuring the revenue reinvested into assets, has reached about 35%. And considering Meta's AI ambitions, this ratio could continue to climb.

META CAPEX to Revenue (Annual) data by YCharts

On Wednesday, as Meta's fresh earnings report unfolds, investors will be looking to see how much capex might grow in the quarters to come and, importantly, whether this spending is translating into growth for Meta. This may offer us clues about the earnings opportunity ahead for this particular company, and it also might provide a few early hints about what to expect from other "Magnificent Seven" companies when they report earnings in the coming days.

There's reason to be optimistic, considering Meta recently launched a key product, its personal AI agent Muse -- and downloads reached record levels. Though these have been free downloads, the app also offers subscriptions for those who aim to use it more. This represents Meta's initial attempts to monetize its AI investments.

Any positive trends noted by Meta could boost the stock and could also lift other AI shares as investors anticipate more good news from other tech giants in the days to come. All of this may happen as early as Thursday, the first trading session after the report. And given AI stocks' major role in stock market movement, Meta's report could offer the S&P 500 direction in the days to come.

The final Oracle (NYSE: ORCL) dividend of 2026 is coming this week, with investors who have secured shares in the software company on time set to receive a payment unchanged from the previous quarters.

Specifically, Oracle will once again pay a quarterly dividend of $0.5 per share on Friday, October 23, 2026. The ex-dividend date of October 9 has long past, meaning only those who held ORCL shares prior to that will be eligible for a payout.

Oracle dividend schedule. Source: Dividend.com At a payout of $0.5, 100 ORCL shares will generate exactly $50 in Oracle stock dividends for the fourth quarter of 2026. Comparatively, 500 shares will earn $250, while 1,000 shares translate into $500.

The payout comes as Oracle stock trades at $129.59, down nearly 13% on the monthly chart. At that price, a 100 ORCL share investment is worth $12,959 at press time. On the ex-dividend date, however, it was worth $14,140, as the stock was changing hands at $141.4 at the time.

Oracle dividend details As mentioned, this week’s payment remains unchanged from the previous quarter. In fact, the last ORCL dividend increase came in the second quarter of 2025, when the payout was lifted from $0.4 to $0.5 per share. In other words, 100 ORCL shares will have netted $200 in taxable dividend income this year.

The company rewards shareholders on a quarterly basis, and it has an average price recovery of 6.2 days. Currently, the payout ratio is at around 18.15%, while the yield sits at 1.54%, slightly above the industry average of 1.37%.

According to the current estimates retrieved from Dividend.com, Oracle’s first 2027 dividend payout could come on January 22, 2027. If predictions are correct, the figure will once again remain unchanged.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Anyone who bought The Trade Desk (TTD +0.24%) on its first day of trading and hung on has seen the stock climb over 40-fold, then give most of it back. The ad tech company's shares finished that first day, Sept. 21, 2016, at $30.10 -- or around $3.01 adjusted for the 10-for-1 stock split in 2021.

At $3.01 a share, $10,000 bought around 3,322 shares. At the stock's $12.23 close on Oct. 16, these shares are worth around $40,600. Put simply, the stake is still worth about four times what it cost, though the stock trades 91% below its December 2024 peak of $139.51.

At that peak, the same stake was worth around $463,000.

But the company held up on the way down, at least until this year. Actually, I think the most telling point is that The Trade Desk makes more per share now than it did at the peak.

Image source: The Motley Fool.

A decade of growthThe Trade Desk's software lets brands and ad agencies bid on digital ad space automatically (what the industry calls a demand-side platform), and the climb was built on its results. Revenue in 2016 was around $203 million. By 2024, it was $2.4 billion, after rising around 36% a year on average. The company made a profit in every one of those years. And spending on its platform hit $12 billion in 2024, a record.

Even the 2022 sell-off didn't break that pattern. The stock lost around half its value that year, but revenue rose about 32% year over year to $1.6 billion.

Shares went on to set their record two years later.

By then, though, investors were paying a lot for that growth. At $139.51, the stock traded at almost 230 times earnings, based on the $0.61 of earnings per share The Trade Desk had generated over the last 12 months. A price-to-earnings ratio like that arguably only made sense if fast growth kept going for many more years.

What did the crash take?The first big drop came with a miss on the company's own forecast. The Trade Desk had guided for fourth-quarter 2024 revenue of at least $756 million, and it reported $741 million. Shares fell 33% a day later, in February 2025.

Worse, the stock shed another 39% in a single session in August 2025, the largest one-day drop since it went public. The company had just said its CFO was leaving, and it guided for third-quarter revenue growth of at least 14% year over year, a slowdown from 19% growth in the second quarter.

Growth kept slowing after that. Revenue climbed 18% year over year in the third quarter of 2025, but only 3% in the second quarter of 2026. And for the third quarter of 2026, management guided for revenue of at least $650 million, around 12% below the year-ago quarter.

The stock even lost its spot in the S&P 500 (^GSPC +0.41%), which it had joined in July 2025. It went to the S&P SmallCap 600 on Sept. 21.

But profits have held up much better than the stock. Over the four quarters through June, The Trade Desk earned $0.84 a share, up from $0.61 at the peak. At $12.23, the stock trades at less than 15 times those earnings.

So most of what the stock gave back was its valuation. The price-to-earnings ratio dropped from almost 230 to below 15, even as earnings per share climbed around 38%. The newer issue is in the guidance, as a shrinking revenue line could eventually cut earnings too.

$12.26+$0.03 (+0.24%)

NASDAQ · As of 4:00 PM ET 10/19/26

An S&P 500 fund did about as wellThat $40,600 works out to an annual return of around 15% over a bit more than 10 years. But $10,000 put in the SPDR S&P 500 ETF Trust (SPY +0.42%) on Sept. 21, 2016, with dividends reinvested, was worth around $41,400 as of Oct. 16 -- a nearly identical return.

The difference was the path. The S&P 500 fund never asked its owner to watch a $463,000 stake shrink to around $40,000, or to ride out two one-day drops of over 30%.

What does this say about holding a fallen growth stock? Mainly that the low entry price made the difference for a first-day holder. A buyer at $3.01 could weather a 91% fall and still quadruple their money.

A buyer at the peak, of course, would need the shares to climb around 11-fold just to break even.

And unlike in 2022, revenue probably won't grow through this slump. Until management's guidance shows growth again, I wouldn't bet on this drop working out the way the 2022 one did.

Most investors know Berkshire Hathaway (BRKA +0.09%) (BRKB +0.04%) is a combination of a portfolio of publicly traded stocks and privately owned businesses like GEICO Insurance, Duracell batteries, and Shaw flooring. Is it possible, however, that investors are underestimating just how much cash the conglomerate is collecting from one of its most boring wholly owned companies? It certainly looks that way.

The business in question is the railroad BNSF, although you may know it better as Burlington Northern Santa Fe. Here's a closer look.

All aboard the cash train!
Contrary to a common assumption, Berkshire Hathaway isn't just a collection of companies that former CEO Warren Buffett and current CEO Greg Abel felt good about owning. Every one of its holdings serves a specific purpose. For instance, the vast majority of its privately held businesses are meant to generate reliable cash flow that backs up its insurance operation.

Berkshire also discloses surprisingly detailed information about these businesses. For instance, through the first half of 2026, BNSF has generated just over $2.9 billion in operating earnings, up nearly 10% year over year. That's more than one-tenth of the organization's total operating earnings -- again.

Image source: Berkshire Hathaway Q2-2026 investor report.

Although operating income is a key measure of a business's health, in this instance it's not necessarily the most meaningful one. Arguably more important to a conglomerate like Berkshire is how much cash an investment is reliably putting in its parent company's pockets, whether that investment is private or a publicly traded one.

To this end, as Greg Abel noted in his 2025 letter to Berkshire Hathaway shareholders, published early this year, $4.4 billion of BNSF's $8.1 billion in 2025 operating earnings was handed over to Berkshire in the form of a cash dividend. The railroad company is on pace to at least match these numbers again this year, extending a long-standing track record of real cash generation.

Image source: Getty Images.

The amazing part? Berkshire Hathaway paid only $34.5 billion for BNSF back in 2010. Now 16 years later, the effective dividend yield on this initial investment is a healthy 12.7%, not to mention the appreciation of the railroad's value in the meantime. Although Berkshire itself doesn't offer a specific figure, estimates of its market value range from $75 billion to as much as $200 billion, and Buffett has been willing to say the railroad is the conglomerate's second-most-valuable asset, mostly due to the cash it produces.

More private, less public?
It's just one piece of the Berkshire puzzle, of course, and a relatively small one at that; Berkshire's current market cap stands at a stunning $1.1 trillion.

It's an important detail, though, and an increasingly important one, particularly if the stock market itself decides to unwind its extreme valuation. Although a correction would put widespread bearish pressure on most stocks, since Berkshire Hathaway's value largely consists of privately held companies, its ticker could be well-shielded from any such weakness.

Given this, shareholders might wish Abel would make more outright acquisitions of small cash-cow companies rather than use Berkshire's $365.5 billion in uninvested cash to simply purchase more stocks. The private approach appears to create more long-term value.

-

After More Than Three Months, the Company Has Refused to Engage on Steel’s Proposal

Steel Believes Directors Breached Their Fiduciary Duties by Demanding Dismissal of Claims Against Them in Exchange for Diligence

Steel’s Offer Delivers Certain Cash at a Premium or Shareholders Can Remain Invested in InMode

Absent Meaningful Engagement, Steel Will Hold the Entrenched Board Accountable

NEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, “Steel”), a significant, long-standing shareholder of InMode Ltd. (“InMode” or the “Company”) (Nasdaq: INMD), today issued an open letter to all InMode stakeholders. The full text of the letter is below.

October 19, 2026

To All InMode Stakeholders:

Steel Partners Holdings L.P. (together with its affiliates, “Steel”) is a significant, long-standing shareholder of InMode Ltd. On July 9, 2026, we proposed to acquire up to 100% of the outstanding shares of InMode for $16.75 per share in cash. More than three months later, that proposal remains in place and we have spent significant time and effort attempting to access information that would enable us to move forward with our offer.

On September 16 the Company disclosed that the competing proposal from the group led by its Chief Executive Officer, Moshe Mizrahy, had expired without a transaction.1 Our proposal is now the only offer outstanding, and today we are setting an expiration date for that proposal of October 30, 2026.

We do not believe the members of this Board have the independence required to fulfill their fiduciary duties in evaluating a proposal from the Company’s own Chief Executive Officer against a competing proposal from an outside shareholder. We have seen firsthand that Mr. Mizrahy and co-founder Dr. Michael Kreindel together control this Company through their conflicted relationships with the other Board members.

The Company Has Not Engaged with Us in Good Faith

In more than three months, the Company has not entered into a non-disclosure agreement, opened a data room or provided any diligence materials. The Special Committee has refused to move forward without a dismissal of our claims against the directors individually. To facilitate productive discussions, we have repeatedly offered to stay those actions for the duration of negotiations.

We believe that conditioning access to diligence information on the discontinuation of our lawsuit surrounding the directors’ own conduct is a blatant breach of their fiduciary duties. The Board and the Special Committee should be using their positions to bring the best available proposal to shareholders, not to secure protection for themselves.

We have been prepared to execute a simple non-disclosure agreement since July. We have spent significant time and effort negotiating with the Special Committee and its advisors in an attempt to obtain information, including flying to Tel Aviv to meet in person with each member of the committee. Every non-disclosure agreement the Company has put in front of us conditions access to basic information on our surrender of our rights as shareholders, including our ability to hold this Board accountable for its conduct.

Over this same period, the Company has not asked us a single question about the details of our offer and has told shareholders nothing about it. The Company has said publicly that it is open to providing information, and that this process would be conducted to the “highest standards of corporate governance, transparency, and objectivity.”2 Its conduct has not matched that statement.

InMode’s Board Is Not Positioned to Evaluate This Proposal

We believe there are significant conflicts of interest on this Board that prevent its members from discharging their fiduciary duties. Evaluating our proposal against the status quo requires directors who are independent of Mr. Mizrahy in substance and not only in title, and the information we have gathered since we first raised these concerns has only reinforced our view that this Board does not meet that standard.

We set out our specific concerns in our prior letters and will not repeat them here. They involve overlapping board service alongside Mr. Mizrahy at other companies, transactions between InMode and companies affiliated with those directors, each approved by those same directors, and a proposed buyer group, led by the Chief Executive Officer, which included InMode’s own manufacturer and its United Kingdom distributor. In our view this Board lacks the independence required to stand up to the Chief Executive Officer and protect the shareholders it is charged with representing.

Management Has Cut Guidance Six Times Since February 2024

The Company last reported results on August 5. Revenue was $95.6 million, flat against the prior year, with gross margin down to 75% from 80% and non-GAAP operating margin down to 17% from 28%.3 The Company also cut full year non-GAAP operating income guidance to a range of $68 million to $73 million, the sixth reduction to earnings guidance since February 20244, and told shareholders it expects these trends to continue for the foreseeable future. At the same time, the Company has significantly curtailed investor communication, including suspending earnings calls, demonstrating the Board’s disregard for the corporate governance and transparency it trumpets.

After a failed strategic review, an expired insider proposal and continued operating uncertainty, shareholders have been given no evidence of a credible plan under current leadership.

Following the Expiration of Our Offer, We Will Hold the Board Accountable

In our view, these directors have breached their duties of loyalty and care. They have failed to supervise a Chief Executive Officer who has run roughshod over the shareholders he is meant to serve, and whose conduct has raised serious questions under U.S. securities laws. A Board that cannot be trusted to oversee management or to run a fair process for a premium, all-cash offer should be replaced by directors the shareholders choose, and we will pursue all available remedies to protect shareholder interests and hold this Board accountable.

Respectfully,

Warren G. Lichtenstein
Executive Chairman
Steel Partners Holdings L.P.

More News From Steel Partners Holdings L.P.

Back to Newsroom

New connected experience designed to help small business owners build and scale their businesses with access to financial, operational and business management AI tools and expertise

, /PRNewswire/ -- The Huntington National Bank ("Huntington") today announced The 1866 Studio, a new AI-powered operating system built with Gemini platform, Google Cloud's AI platform. Named for the year Huntington was founded, The 1866 Studio honors the bank's legacy of empowering businesses by bringing together business guidance, financial intelligence, digital tools and human expertise into a single, connected experience for aspiring and existing small business owners.

Huntington Bank Introduces The 1866 Studio, an AI-Powered Small Business Operating System Built with Google Cloud

The 1866 Studio Desktop

The 1866 Studio Business Profile

The 1866 Studio Mobile

The 1866 Studio Call to Action

Experience the full interactive Multichannel News Release here: https://www.multivu.com/huntington/9347252-en-huntington-bank-announces-the-1866-studio 

The 1866 Studio is designed to simplify the complex and time-consuming demands of starting and running a business. The operating system will provide agentic AI workflows across the financial, operational and management needs of business owners that streamline complex work and help them move from information to intelligence to action. By retaining relevant business context across tasks, The 1866 Studio enables business owners to orchestrate decisions across disparate tools while maintaining control as their needs evolve.

"Small businesses are essential to strong communities and a strong economy, and helping businesses thrive has been central to Huntington's purpose for more than 160 years," said Brant Standridge, president of Huntington Bank. "We are continually looking for new ways to help business owners navigate challenges, seize opportunities and spend more time focused on the financial success and growth of their businesses. The 1866 Studio is the next evolution of that commitment, bringing together Huntington's expertise and Gemini platform to help owners make more informed decisions and spend more time building the businesses they imagined."

The 1866 Studio will leverage Huntington's extensive small business and financial expertise and an AI-powered experience built using Google Cloud's comprehensive platform to build, scale, govern and optimize agents. Combined with Google's multimodal Gemini models, Gemini platform is enabling Huntington to offer business owners an intelligent, connected operating system that helps them navigate decisions with greater confidence and efficiency.

"Small business owners shouldn't have to become experts in every function or in AI to build a successful business," said Vijay Konduru, head of innovation and AI products at Huntington. "The 1866 Studio is an AI-powered platform designed around the small business jobs to be done. As the product evolves, it's intended to increasingly support the full range of those jobs across the business lifecycle, from turning an idea into a business to running and growing it, and ultimately preparing for succession, sale or exit."

"The future of small business banking is about delivering expertise and guidance in the moments customers need it most," said Rohit Bhat, general manager and managing director, Financial Services, Google Cloud. "By using Gemini platform and Gemini frontier models to build The 1866 Studio, Huntington is creating an innovative experience that helps small business owners move from information to action."

Initial AI capabilities of The 1866 Studio, including agentic workflows, equip entrepreneurs to turn business ideas into actionable plans, navigate startup requirements, strengthen their brand, identify funding sources, enable funding readiness and plan for growth. For example:

Business launch support: With built-in AI agents, owners can navigate the steps required to start a business, from entity selection and registration to licensing and operational setup, while generating a customized action plan to help move from idea to launch.
Marketing & campaign creation: Leveraging multimodal Gemini models, owners can instantly generate tailored marketing collateral, digital ad copy and social media campaigns.
Loan readiness assistance: AI-powered agents help owners evaluate financing readiness by identifying potential gaps, explaining lender expectations and recommending actions that can strengthen eligibility for future financing opportunities.
"Agentic AI workflows that help carry out tasks are one part of this end-to-end operating system," Konduru added. "Alongside them are relevant, personalized expert content and an AI assistant that helps owners both monitor their business operations and finances and manage and orchestrate daily work. Together, these capabilities help owners move from advice to action with support that evolves with the business, while they remain in control."

The 1866 Studio builds on Huntington's multi-year strategic partnership with Google Cloud to modernize technology, advance governed AI capabilities and accelerate innovation. Through the partnership, Huntington continues to explore new ways to use technology built with Google Cloud to enhance experiences for customers, colleagues and the communities and businesses it serves.

Interested small business owners and entrepreneurs, not limited to Huntington customers, can sign up for early access to The 1866 Studio beginning Oct. 19.

Visit Huntington.com/The1866Studio to sign up for early access to The 1866 Studio.

About Huntington
Huntington Bancshares Incorporated is a $284 billion asset regional bank holding company headquartered in Columbus, Ohio. A top 10 U.S. commercial bank, The Huntington National Bank and its affiliates provide consumers, small and middle-market businesses, corporations, municipalities, and other organizations with a comprehensive suite of banking, payments, wealth management, and risk management products and services. Founded in 1866, Huntington operates over 1,400 branches in 21 states, with certain businesses operating nationally. Visit Huntington.com for more information.

SOURCE Huntington Bank

New pre- and post-market sessions bring more access to U.S.-listed options Trading launched today with options on 24 single stocks and 5 ETFs Several global brokers are supporting the launch , /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced select multi-listed equity and exchange-traded fund (ETF) options are available to trade during extended pre-market and post-market sessions on its Cboe Options Exchange (C1). C1 is currently the only U.S. options exchange offering pre- and post-market index options sessions and is now expanding trading hours for select U.S. equity single-stock and ETF options.

Trading of select single-stock and ETF options is now available during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and a post-market session from 4:00 p.m. to 4:15 p.m. ET, Monday to Friday, covering some of the most actively traded and liquid symbols, including the Magnificent 10 stocks and other widely followed U.S.-listed names plus major ETFs. The full list of underlying symbols is: AAPL, AMD, AMZN, AVGO, BABA, BAC, F, GLD, GOOG, GOOGL, HOOD, INTC, IWM, META, MRVL, MSFT, MU, NFLX, NOK, NVDA, ORCL, PFE, PLTR, QQQ, SNDK, SPY, TSLA, TSM, XLF.

Through September, options on these names accounted for approximately 53% of average daily U.S.-listed options volume in 2026.  

"Building on our 53-year history of innovation and our expertise in offering expanded hours for our flagship index options, Cboe led this important initiative with extensive input from retail and institutional participants including our U.S. and non-U.S. broker partners, whose insights were critical to a successful launch today," said Rob Hocking, Global Head of Derivatives at Cboe. "The shift to 24x5 trading across asset classes is only accelerating, and that's been apparent in the demand for Cboe's index options during non-traditional hours, particularly leading up to the U.S. market open when economic data and corporate announcements are commonly released. Now, with the addition of extended trading hours for options on single stocks and ETFs, global investors will be able to manage positions and risk with more flexibility in many of the names that drive today's market."   

Several brokers globally are offering or plan to offer access to the sessions.

Josh Krugman, SVP, brokerage at Fidelity Investments, said: "Options have long been an important tool for Fidelity investors seeking to manage risk and pursue market opportunities. Cboe's extended trading hours represent a meaningful evolution for the options market, giving investors greater flexibility and choice in how and when they engage with these strategies."

Milan Galik, Chief Executive Officer of Interactive Brokers, said: "Markets move around the clock, but trading hours for US equity options have remained limited. We welcome Cboe's initiative to narrow that gap, giving investors around the world more flexibility to trade and manage risk outside regular US market hours."

Neil McDonald, CEO of Moomoo US, said: "We're proud to partner with Cboe to offer our customers access to extended trading hours for select equity options from day one. Earnings announcements and economic developments don't follow the market's trading schedule. This expansion gives retail investors more flexibility to manage their positions and respond to market-moving news before the opening bell and after the close."

Abhishek Fatehpuria, VP of Product Management at Robinhood, said: "Many of our customers are early risers who want to catch up on the news and look for market signals before the opening bell. With Cboe's new extended hours options trading, we're making it easier for customers to trade on their own schedule, both before or after the bell. This is just another example of our commitment to making Robinhood the best place for active traders."

Ian Leong, Chief Executive Officer, Tiger Brokers Singapore, said: "For investors in Singapore, the U.S. pre-market falls in our evening, when much of the news that moves U.S. stocks is released. Our clients have long told us they want greater flexibility to manage their positions around these events, and our partnership with Cboe enables us to deliver on that need. Extending access to selected U.S. equity options is another step in our commitment to innovation and giving clients more choice in how they trade, alongside the education and risk controls needed for trading outside regular hours."

John Bartleman, President and Chief Executive Officer of TradeStation Group, Inc., said: "Cboe's expansion of options trading hours gives traders greater flexibility to respond to market-moving events as they happen. We believe traders deserve access to the markets when opportunity strikes, which is why TradeStation Securities is making extended-hours options trading available to its clients at launch. Clients will be able to act on their strategies in select options before the open and after the close, using the same integrated tools, education, and support they rely on every day across our trading ecosystem."

Peter Laptewicz, CPO, Tradier, said: "Markets don't wait for the opening bell, and neither should our clients. Cboe's GTH equities options session will give Tradier clients the flexibility to react to market-moving events in real time, rather than having to wait for regular trading hours. We're proud to support Cboe in expanding access and opportunity for active traders."

Cboe currently offers near 24x5 trading of several of its proprietary index options in its Global Trading Hours (GTH) (8:15 p.m. ET to 9:25 a.m. ET) and Curb Trading Hours (4:15 p.m. ET to 5:00 p.m. ET) sessions. GTH trading achieved record monthly and quarterly average daily volume in September and the third quarter of 2026.

Cboe's U.S. equities business currently operates trading from 4 a.m. ET to 8 p.m. ET, Monday through Friday, on two of its exchanges, and plans to launch trading 23 hours a day, 5 days a week on its Cboe BZX Exchange on December 6, subject to industry readiness. Cboe will not open a class of options if the underlying security has not opened and will generally halt an options class if its associated underlying security halts.

For more information on the new pre- and post-market options sessions, visit Equity Options Extended Trading Hours FAQ.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world's first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world's leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.

Cboe Media Contacts

Cboe Analyst Contact

Angela Tu

Tim Cave

Kenneth Hill, CFA

+1-646-856-8734

+44 (0) 7593-506-719

+1-312-786-7559

[email protected]

[email protected]

[email protected]

CBOE-C
CBOE-OE

Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks or service marks of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor's Financial Services LLC. All other trademarks and service marks are the property of their respective owners. 

Options involve risk and are not suitable for all investors. Prior to buying or selling an option, a person must receive a copy of Characteristics and Risks of Standardized Options (ODD). Copies of the ODD are available from your broker or from The Options Clearing Corporation, 125 S. Franklin Street, Suite 1200, Chicago, IL 60606.

Cboe Global Markets, Inc. and its affiliates do not recommend or make any representation as to possible benefits from any securities, futures or investments, or third-party products or services. Cboe Global Markets, Inc. is not affiliated with S&P or the third-party sites referenced in this press release. Investors should undertake their own due diligence regarding their securities, futures, and investment practices. This press release speaks only as of this date. Cboe Global Markets, Inc. disclaims any duty to update the information herein.

Nothing in this announcement should be considered a solicitation to buy or an offer to sell any securities or futures in any jurisdiction where the offer or solicitation would be unlawful under the laws of such jurisdiction. Nothing contained in this communication constitutes tax, legal or investment advice or a recommendation to buy or sell a security, future, or other financial product. Investors must consult their tax adviser or legal counsel for advice and information concerning their particular situation.

Cboe Global Markets, Inc. and its affiliates make no warranty, expressed or implied, including, without limitation, any warranties as of merchantability, fitness for a particular purpose, accuracy, completeness or timeliness, the results to be obtained by recipients of the products and services described herein, or as to the ability of the indices referenced in this press release to track the performance of their respective securities, generally, or the performance of the indices referenced in this press release or any subset of their respective securities, and shall not in any way be liable for any inaccuracies, errors. Cboe Global Markets, Inc. and its affiliates have not calculated, composed or determined the constituents or weightings of the securities that comprise the third-party indices referenced in this press release and shall not in any way be liable for any inaccuracies or errors in any of the indices referenced in this press release.

There are important risks associated with transacting in any of the Cboe Company products discussed here. Before engaging in any transactions in those products, it is important for market participants to carefully review the disclosures and disclaimers contained at: https://www.cboe.com/us_disclaimers/.

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as "may," "might," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our  clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

SOURCE Cboe Global Markets, Inc.

Please see below information about transactions made under the third tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 22 July 2026.

The duration of the buy-back tranche: 23 July to no later than 26 October 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 22 July 2026, available here: https://newsweb.oslobors.no/message/678529

From 12 October to 16 October 2026, Equinor ASA has purchased a total of 540,275 own shares at an average price of NOK 425.4849 per share.

Overview of transactions:

DateTrading venueAggregated daily volume (number of shares)Daily weighted average share price (NOK)Total daily transaction value (NOK)     12 OctoberOSE137,775418.322457,634,368.66 CEUX    TQEX        13 OctoberOSE137,500420.993457,886,592.50 CEUX    TQEX        14 OctoberOSE132,000431.516956,960,230.80 CEUX    TQEX        15 OctoberOSE    CEUX    TQEX        16 OctoberOSE133,000431.561557,397,679.50 CEUX    TQEX        Total for the periodOSE540,275425.4849229,878,871.46 CEUX    TQEX        Previously disclosed buy-backs under the trancheOSE7,697,832396.52413,052,375,860.73CEUX   TQEX   Total7,697,832396.52413,052,375,860.73     Total buy-backs under the tranche (accumulated)OSE8,238,107398.42343,282,254,732.19CEUX   TQEX   Total8,238,107398.42343,282,254,732.19 Following completion of the above transactions, Equinor ASA owns a total of 23,077,317 own shares, corresponding to 0.97% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 11,773,082 own shares, corresponding to 0.49% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: An overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Detailed overview of transactions

New TREMFYA® (guselkumab) 3-year as-observed data show clinical remission rates of up to 94% (172/183 patients) and endoscopic remission rates of up to 52% (89/172 patients) in adults with moderate to severe Crohn’s disease in the 100 mg q8w dose group1FUZION data show combined fistula remission was maintained through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg q8w dose group2Together, these findings expand the evidence for guselkumab across long-term disease management and one of the most difficult-to-treat manifestations of Crohn’s disease1,2 BEERSE, BELGIUM (19 October 2026) – Johnson & Johnson today announced new data that further expands the clinical evidence supporting TREMFYA® (guselkumab) in Crohn's disease (CD) at the 2026 United European Gastroenterology Week (UEG Week). Research from the Phase 3 GALAXI studies shows durable efficacy and a consistent safety profile for guselkumab through three years (Week 144) of maintenance treatment in adults with moderately to severely active CD, reinforcing its long-term benefit in this chronic, progressive disease.1 Additionally, late-breaking one-year results from the Phase 3 FUZION study showed that guselkumab maintained or improved fistula remission through Week 48 in adults with CD with perianal fistula.2

"The treatment goals in Crohn's disease continue to evolve beyond short-term symptom management towards achieving durable disease control that can be sustained over years," said Mark Graham, Therapeutic Area Head, Immunology, J&J Innovative Medicine EMEA. "These findings reinforce the potential of guselkumab across different stages and manifestations of Crohn's disease, from sustained remission over three years to encouraging outcomes in patients living with perianal fistula, one of the most challenging complications of the disease."

Crohn’s disease is one of the two main forms of inflammatory bowel disease (IBD), which affects an estimated two million people across Europe.3 Guselkumab is an IL-23p19 subunit inhibitor approved in IBD that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,5,6,7 Findings for the unique mechanism of action are limited to in vitro studies, and the clinical significance of this finding is not known.8 IL-23 is a cytokine secreted by activated monocytes/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases, including Crohn’s disease.9

Three-year GALAXI results support the known efficacy and safety profile of guselkumab

Patients in the GALAXI 2 and 3 studies received intravenous induction followed by one of two guselkumab maintenance dosing regimens: 100 mg administered subcutaneously every eight weeks (q8w; n=286) or 200 mg administered subcutaneously every four weeks (q4w; n=296).1 In total, 432/582 patients continued treatment through Week 144.1 These were as-observed analyses and do not represent outcomes in the full randomised population.1 Participants who discontinued, lacked Week 144 data or underwent dose adjustment were not included.1 Across both regimens, clinical and endoscopic remission were maintained through three years of treatment.1 At Week 144 in the long-term extension (LTE), the data show:a

94% (172/183) of patients receiving guselkumab 100 mg q8w and 91% (185/204) receiving guselkumab 200 mg q4w achieved clinical remission.b,189% (162/183) of patients receiving guselkumab 100 mg q8w and 88% (179/204) receiving guselkumab 200 mg q4w achieved 90-day corticosteroid-free clinical remission.152% (89/172) of patients receiving guselkumab 100 mg q8w and 61% (119/195) receiving guselkumab 200 mg q4w achieved endoscopic remission.c,174% (432/582) of guselkumab-treated patients remained on treatment through three years.1 Safety findings through Week 144 were consistent with the known safety profile of guselkumab in Crohn’s disease.1 Common adverse reactions associated with guselkumab include respiratory tract infections, diarrhoea, and injection site reactions.4

The three-year results demonstrate durable clinical, corticosteroid-free and endoscopic remission across both guselkumab maintenance regimens.1

"In a chronic condition such as Crohn's disease, maintaining remission is as important as achieving it," said Prof. Silvio Danese, Gastroenterologist and Professor of Gastroenterology at Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital in Milan, Italy.d "The three-year GALAXI results provide valuable longer-term evidence, showing that high levels of clinical remission were accompanied by sustained endoscopic and corticosteroid-free outcomes across both guselkumab maintenance regimens."

New FUZION 48-week analysis extends evidence in Crohn’s disease with perianal fistula

The 48-week findings showed that combined fistula remission, which incorporates both clinical and radiological assessment, was maintained or improved in both guselkumab maintenance regimens.2 Among patients initially randomised to the guselkumab 100 mg q8w maintenance regime (n=113), combined fistula remissione further increased from 28% at Week 24 to 35% at Week 48.2,10 Results at Week 48 include patients who underwent blinded dose adjustment to guselkumab 200 mg every four weeks at Week 24 (n=55).2 Similar findings were observed for rates of clinically assessed fistula remission.f,2

Results among patients receiving guselkumab 200 mg every 4 weeks (q4w; n=115) remained consistent through Week 48 (27% at Week 24 to 26% at Week 48).2,10 Similar findings were observed for clinically assessed fistula remission.2 Overall, 90% of all randomised patients, which included both bio-naïve and bio-experienced patients, completed treatment through Week 48.2

“Perianal fistula remains one of the most debilitating complications of Crohn's disease, where achieving durable disease control beyond symptom improvement is a challenge,” said Ailsa Hart, Ph.D., Director of St Mark's Hospital Inflammatory Bowel Disease Research, Consultant Gastroenterologist, and study investigator.g “The latest findings from the FUZION study show that patients treated with guselkumab maintained or improved upon the clinical benefits observed at Week 24, providing encouraging evidence for its use in this patient population.”

Safety findings through Week 48 were consistent with the known safety profile of guselkumab in Crohn’s disease.2 Common adverse reactions associated with guselkumab include respiratory tract infections, diarrhoea, and injection site reactions.4

These results reinforce the previously shared Week 24 results from FUZION,2,10 making guselkumab the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomised, placebo-controlled trial in patients with Crohn’s disease with perianal fistula, one of the most difficult-to-treat manifestations of the disease.2

Together, the GALAXI and FUZION findings presented at UEG Week 2026 underscore the growing breadth of evidence supporting guselkumab across Crohn's disease, from sustained long-term remission in moderately to severely active disease to efficacy in patients living with complex fistulising complications.1,2,11

Editor’s notes:

The Week 144 clinical remission, 90-day corticosteroid-free clinical remission and endoscopic remission results above represent the as observed data for the three-year GALAXI analysis.1 The observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 144; participants who had a dose adjustment were not included.1Clinical remission was defined as a CDAI score <150.1Endoscopic remission was defined as an SES-CD ≤4, with a ≥2-point reduction and no subscore >1 on any subcomponent.1Silvio Danese is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.Combined fistula remission was defined as 100% closure of all external openings without development of new fistulas or abscesses and without any drainage by external openings, occurring spontaneously or after gentle finger compression and absence of collections >2cm of the perianal fistulas in at least two of three dimensions, confirmed by a blinded central review of the MRI results.2Clinically assessed fistula remission was defined as: 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by external openings, occurring spontaneously or after gentle finger compression.2Ailsa Hart is a paid consultant for Johnson & Johnson. She has not been compensated for any media work. About the GALAXI programme (EudraCT 2017-002195-13)12

GALAXI is a double-blind, placebo-controlled, active-controlled (ustekinumab), parallel group, global, multicentre Phase 2/3 programme designed to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease with inadequate response/intolerance to conventional therapies (immunomodulators, corticosteroids) and/or biologics (infliximab, adalimumab, certolizumab pegol, vedolizumab).12 GALAXI includes a Phase 2 dose-ranging study (GALAXI 1) and two independent, identically designed confirmatory Phase 3 studies (GALAXI 2 and 3, n=1021).12 Each GALAXI study employed a treat-through design in which participants remained on the treatment to which they were initially randomised and includes a long-term extension that will assess clinical, endoscopic, and safety outcomes with guselkumab through a total of five years.4,12,13 Clinical outcomes include clinical remission (Crohn's Disease Activity Index [CDAI] <150), while endoscopic outcomes include endoscopic response and endoscopic remission as assessed using the Simple Endoscopic Score for Crohn's Disease (SES-CD).12

About the FUZION study (EudraCT 2021-000491-10)14

FUZION is a randomised, placebo-controlled, double-blind, multicentre, Phase 3 study designed to evaluate the efficacy and safety of guselkumab in adults with Crohn’s disease with perianal fistula.14 Patients enrolled in the study had one or more active draining perianal fistulas confirmed by blinded central MRI review, Crohn’s Disease Activity Index [CDAI] <350, and inadequate response to oral corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, or up to 2 advanced therapy classes.10,14 Patients were randomised 2:2:1 to receive guselkumab 200 mg intravenous (IV) induction at Weeks 0, 4, 8 followed by guselkumab 100 mg subcutaneous (SC) maintenance therapy every 8 weeks (q8w); or guselkumab 200 mg IV infusion at Weeks 0, 4, 8 followed by guselkumab 200 mg SC maintenance therapy every 4 weeks (q4w); or placebo.10

About Crohn’s disease

Crohn’s disease is one of the two main forms of inflammatory bowel disease, which affects an estimated two million people across Europe.3 Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.15 Symptoms of Crohn’s disease can vary, but often include abdominal pain and tenderness, frequent diarrhoea, rectal bleeding, weight loss, and fever.16 There is currently no cure for Crohn’s disease.17

About guselkumab

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,5,6,7 Findings for the unique mechanism of action are limited to in vitro studies, and the clinical significance of this finding is not known.8

Guselkumab is approved in the EU for the treatment of moderate to severe plaque psoriasis (Pso) in adults who are candidates for systemic therapy and for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug therapy.4 It is also approved in the EU and U.S. for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a JAK inhibitor and for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.4,18

Johnson & Johnson maintains exclusive worldwide marketing rights to guselkumab.

Guselkumab important safety information

In controlled periods of clinical studies with guselkumab, adverse drug reactions (ADRs) that consisted of respiratory tract infections were very common (≥10 percent); increased transaminases, headache, diarrhoea, arthralgia, rash and injection site reactions were common (≥1 to <10 percent); and herpes simplex infections, tinea infections, gastroenteritis, decreased neutrophil count, hypersensitivity, anaphylaxis, and urticaria were rare ADRs (≥0.1 percent to <1 percent).4

Please refer to the Summary of Product Characteristics for full prescribing information for guselkumab: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/innovativemedicine/emea/

Follow us at https://www.linkedin.com/company/jnj-innovative-medicine-emea.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Media contact:
Sophie Daneau
[email protected]

Investor contact:
Jessica Margevich
[email protected]

CP-606720
October 2026

References

Sands BE, et al. Efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s disease: results through week 144 from the phase 3 GALAXI 2 & 3 studies. Oral presentation (OP105) at the United European Gastroenterology Week Congress (UEGW). October 2026.Hart A, et al. Efficacy and safety of guselkumab in perianal fistulizing Crohn’s disease: Week 48 results from the Phase 3, randomized, double-blind, placebo-controlled FUZION trial. LB09 at the United European Gastroenterology Week Congress (UEGW). October 2026.Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.EU SmPC: European Medicines Agency. TREMFYA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf . Accessed October 2026.EU SmPC: European Medicines Agency. Ilumetri Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf. Accessed October 2026.EU SmPC: European Medicines Agency. Skyrizi Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf. Accessed October 2026.EU SmPC: European Medicines Agency. Omvoh Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/omvoh-epar-product-information_en.pdf. Accessed October 2026.Sachen KL, et al. Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling. J Crohns Colitis. 2025; 12;16:1532852. Available at: https://doi.org/10.3389/fimmu.2025.1532852.Schinocca C, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Frontiers in Immunology. 2021 Feb 22;12:321. Available at: https://doi.org/10.3389/fimmu.2021.637829.Sands BE, et al. Efficacy of guselkumab in perianal fistulizing Crohn’s disease: Week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study. P5691 at ACG Annual Scientific Meeting 2026. October 2026.Schubert S, et al. Early symptomatic response to guselkumab in inflammatory bowel disease: first real-world data from the german GORGEOUS study. ePoster (PP1357) at the United European Gastroenterology Week (UEGW). October 2026.EU Clinical Trials Register. Clinicaltrialsregister.eu. A Phase 2/3, randomised, double-blind, placebo- and active-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease (GALAXI). Identifier: 2017-002195-13. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002195-13/ES. Accessed October 2026.ClinicalTrials.gov. A Study of the efficacy and safety of guselkumab in participants with moderately to severely active crohn's disease. Identifier: NCT03466411. Available at: https://clinicaltrials.gov/study/NCT03466411#study-plan. Accessed October 2026.ClinicalTrials.gov. A study of guselkumab in participants with fistulizing, perianal Crohn’s disease (FUZION CD). Identifier: NCT05347095. Available at: https://clinicaltrials.gov/study/NCT05347095. Accessed October 2026.Crohn’s & Colitis Foundation. Causes of Crohn’s disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed October 2026.Crohn’s & Colitis Foundation. Signs and symptoms of Crohn’s disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/symptoms. Accessed October 2026.NHS. Crohn’s disease treatment. Available at: https://www.nhs.uk/conditions/crohns-disease/treatment/. Accessed October 2026.U.S. Food and Drug Administration. TREMFYA Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s009lbl.pdf. Accessed October 2026.

-

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced the final close of Blackstone Energy Transition Partners V (“BETP V”) at $8.7 billion – more than 50% larger than its predecessor vehicle. The significantly oversubscribed fund reached its hard cap and builds on the strong performance of the strategy’s prior vintages.

Blackstone Energy Transition Partners (“BETP”) seeks to build energy companies at scale that deliver cleaner, more reliable and more affordable energy to meet growing global needs. BETP’s energy transition investments have generated, as of June 30, a 34% net IRR since 1997, reflecting the strength of its differentiated strategy. In 2025, BETP was named IJ Investor’s “Fund Manager of the Year – Equity” for North America, recognizing its leadership in delivering investment performance at scale.

David Foley, Global Head of Blackstone Energy Transition Partners, said: “We believe there is a generational opportunity for experienced investors in the energy transition to provide solutions to the challenges posed by growing demand for electricity. By backing exceptional management teams with flexible, patient equity capital to increase manufacturing capacity, recruit and train skilled labor and construct new critical energy infrastructure assets, BETP is delivering those solutions and in the process building these companies to scale, creating jobs and generating lasting value for our investors. We are deeply grateful for the trust of our investors and look forward to deploying BETP V in investments that advance the transition to a more affordable, reliable and cleaner energy future.”

BETP V began its investment period in June and has already funded three distinct platform companies (Kindle, Fisterra and Viridon) backing proven management teams to develop and operate new power generation and electric transmission lines, and has also made three acquisitions focused on energy efficiency and resiliency, including:

Flow Control Holdings – a rapidly growing, leading U.S. provider of highly engineered flow control solutions and components for data center liquid cooling, a more energy efficient alternative to air cooling Dresser Utility Solutions – the leading North American provider of measurement (meters), control (regulators, pressure relief valves) and infrastructure repair products for gas and water utilities DarkVision – a provider of innovative, technology-enabled asset inspection services that enhance the safety, reliability and productivity of critical energy infrastructure Since January 2025, BETP has committed over $11 billion in new equity investments across the energy transition ecosystem. This includes transactions in critical energy equipment manufacturers (Maclean Power Systems, Delta Star, Power Grid Components, Arlington Industries, Advanced Cooling Technologies), essential services (Alliance Technical Group, Shermco), energy data analytics (Enverus) and highly-efficient natural gas-fired power infrastructure (Hill Top Energy Center, Wolf Summit Energy, and Potomac Energy Center).

In addition, BETP has successfully monetized several of its mature investments in predecessor funds over the same period, including:

Reaching an agreement to sell Aypa Power, a leading North American battery storage platform with a 6.0 GW portfolio of storage assets Selling a majority interest in Sabre Industries, a leading manufacturer of highly-engineered critical infrastructure for power utilities, telecom and data centers Completing the IPO of Legence (NASDAQ: LGN), a premier provider of specialty mechanical contracting and engineering services for mission critical data center, healthcare and high-specification C&I end markets About Blackstone Energy Transition Partners:

Blackstone Energy Transition Partners is Blackstone’s strategy for control-oriented equity investments in energy-related businesses, a leading energy investor with a successful long-term record, having committed over $34 billion of equity globally across a broad range of sectors within the energy industry. The strategy generally excludes investments in the ownership of hydrocarbon reserves and the extraction thereof. (The returns shown above similarly exclude such upstream investments despite the fact that earlier fund vintages were not managed to exclude such investments.) Blackstone Energy Transition Partners’ investment philosophy is based on backing exceptional management teams with flexible capital to provide solutions that help energy companies grow and improve performance, thereby delivering more reliable, affordable and cleaner energy to meet the needs of the global community. In the process, Blackstone Energy Transition Partners builds stronger, larger scale enterprises, creates jobs and generates lasting value for its investors, employees and all stakeholders. Further information is available at https://www.blackstone.com/our-businesses/blackstone-energy-transition-partners/.

About Blackstone:

Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s over $1.3 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.

More News From Blackstone

Back to Newsroom

, /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced plans to launch new European dairy futures and options contracts before the end of 2026, pending all regulatory reviews.

 The company will introduce new futures and options contracts for European Skimmed Milk Powder, European Butter, European Whey Powder and European Liquid Milk as a first step toward regional expansion following an agreement with the European Energy Exchange earlier this year.

These products will position CME Group to expand on recent record activity within the Dairy complex, including reaching record monthly open interest of an average 420,922 contracts a day in September, a 42% increase year over year, and an all-time daily open interest record of 461,493 contracts on September 29.

"We've long served the dairy community across the U.S., and now we're bringing that same commitment to Europe," said John Ricci, Global Head of Agricultural Products at CME Group. "By offering futures and options, we're giving participants a more complete toolkit to deploy capital efficiently and manage regional price risk - all on a single platform alongside our U.S. complex."

The new contracts will be financially settled and will initially track EEX indices before transitioning to CME Group indices. They will be listed on and subject to the rules of CME.

CME Group and EEX are also working to transition the EEX Weekly European Cheese Indices and the Pan European Butter Index to CME Group for continued benefit to the industry.

For more information on CME Group's dairy products, please visit here. 

As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals.  The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform.  In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing. 

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners. 

CME-G

SOURCE CME Group

In recent years, investors have closely followed quantum computing. If successful, the technology could increase computing speeds exponentially.

The problem with this technology is the delicate nature of quantum bits (qubits) and high error rates. Such challenges mean that widespread commercial viability is likely several years away.

However, companies of all sizes are working to make the technology viable, and if successful, it could dramatically transform companies and the tech industry at large. Knowing this, if I could only invest $1,000, I would choose IonQ (IONQ -1.60%) as my quantum computing stock. Here's why.

Image source: Getty Images.

What about other quantum computing companies? To be clear, I regard this as one $1,000 investment within a diversified portfolio. IonQ is a risky choice, and I would consider this a speculative investment.

Long-time tech investors might remember that numerous internet information companies emerged before Google's parent company, Alphabet, became the dominant search engine. Likewise, the quantum computing industry is likely to undergo a similar shakeout.

This poses a significant risk to IonQ and to start-up peers such as Rigetti Computing and D-Wave Quantum. These companies, IonQ included, are all-in on the technology, and it is unclear how they will survive if they fail to become top players in the quantum computing industry.

For the more risk-averse investors, Alphabet and IBM are also quantum computing investment options. The fact that these are established tech businesses bodes well for the stocks. Still, they only earn a negligible amount of revenue from the technology, which makes it debatable whether one can call them "quantum computing stocks" in any meaningful sense.

IONQ IonQ$30.78-$0.50 (-1.60%)

NYSE · As of 4:00 PM ET 10/19/26

The state of IonQ IonQ's competitive advantages have also eased many of my concerns about the company. It has taken a different path than Google or IBM by utilizing trapped-ion technology. The trapped ions can hold their quantum states longer. That reduces error rates and differentiates the company from its more established competitors.

Moreover, it operates as a quantum-as-a-service (QaaS) model. Thus, it is the only provider natively integrated with Google Cloud, Microsoft's Azure Quantum, and Amazon's Braket.

Additionally, IonQ is a partner of the industry's top chip company, Nvidia. IonQ seems to be following Nvidia's playbook in quantum, which makes the agreement appropriate.

Under the terms of the deal, Nvidia will link its AI supercomputing rack with IonQ's Superion 256 system. They will also orchestrate joint workloads on Nvidia's CUDA-Q platform, allowing Nvidia's GPUs and IonQ's QPUs to work seamlessly with one another, giving it an edge over competitors.

Despite these attributes, IonQ remains financially risky. Even with a 412% yearly revenue increase in the first half of 2026, it experienced $273 million in negative free cash flow during the same period.

IonQ has more than $2.1 billion in liquidity for now. That would imply nearly four years' worth of liquidity at current burn rates. Still, with commercial viability years away, it may need to eventually issue more shares or debt.

Furthermore, its valuation bears little relation to its condition. Its price-to-sales (P/S) ratio is 44, and the 26 forward P/S ratio offers little comfort to those looking for a better value.

However, if IonQ successfully leverages its competitive advantages and partnerships, the stock could experience considerable gains over time. That alone could make it worthwhile to risk $1,000 on IonQ's future.

Moving forward with IonQ stock It could be worth it for risk-tolerant investors to invest $1,000 in IonQ stock.

As a start-up, IonQ is not in a strong financial position, and since it has no obvious Plan B if it fails to succeed in quantum computing, investors face a serious risk of losing their investments.

Nonetheless, many investors are comfortable taking a $1,000 chance on a speculative stock within a diversified portfolio. Despite its limited resources, it has shown promising results using its trapped-ion technology. Moreover, the fact that it persuaded Nvidia to partner with it dramatically increases its chance of success.

Ultimately, if one has the appetite for risk and the foresight to back a technology with limited commercial viability in the foreseeable future, it may be worth taking a chance on IonQ stock.